Companies /Healthcare

Envista Holdings Corp

NYSE: NVST Medical Instruments & Supplies
$27.28
▼ $0.32 (−1.14%) today
Markets closed · 5:17pm ET

Q4 2025 Earnings

Reported Feb 5, 2026, 4:11pm ET · SEC source
$0.38
Beat +17.65%
EPS · est. $0.32
$750.6M
Beat +10.39%
Revenue · est. $680.0M
−6.5%
Trailing market
NVST vs S&P since report
5 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−6%0+6%+12%Feb 5Feb 6report 4:11pm ETearnings+2.0%+12.7%
−6%0+6%+12%Feb 5Feb 6earnings+2.0%+12.7%
NVST +12.7%S&P 500 +2.0%
−6%0+6%+12%Feb 5Feb 6report 4:11pm ETearnings+2.2%+12.7%
−6%0+6%+12%Feb 5Feb 6earnings+2.2%+12.7%
NVST +12.7%NASDAQ +2.2%
−8%0+8%Feb 4Feb 13report 4:11pm ETearnings+1.0%+5.3%
−8%0+8%Feb 4Feb 13earnings+1.0%+5.3%
NVST +5.3%S&P 500 +1.0%
−8%0+8%Feb 4Feb 13report 4:11pm ETearnings+1.6%+5.3%
−8%0+8%Feb 4Feb 13earnings+1.6%+5.3%
NVST +5.3%NASDAQ +1.6%
+17.77%
Day of report
+0.89%
Next session
−0.45%
One week
−8.56%
30 days

S&P 500 over the same 30 days: −2.07%.

Did NVST Beat Earnings? Q4 2025 Results

Envista Holdings delivered a notably strong Q4 2025, beating Wall Street expectations on both the top and bottom lines as broad-based momentum across its dental portfolio drove results well ahead of forecasts. The company posted revenue of $750.60 million, up 15.0% year-over-year and ahead of the $679.95 million consensus estimate by 10.39%, while adjusted diluted EPS of $0.38 beat the $0.32 consensus by 17.65%, rising 58% from $0.24 a year ago. The quarter's outperformance was anchored by strength in both operating segments, with Specialty Products & Technologies reporting 15.8% reported revenue growth and adjusted operating margin expanding sharply to 16.2% from 11.5%. A notable operational milestone, Spark clear aligners turning adjusted operating margin positive in the second half of 2025, underscored the company's improving profitability trajectory. The results prompted at least one analyst firm to upgrade its rating on the stock, which surged more than 23% following the report. Looking ahead, Envista guided for 2026 core sales growth of 2% to 4% and adjusted diluted EPS of $1.35 to $1.45.

Key Takeaways
  • 10.8% core revenue growth in Q4 2025
  • Positive growth in all major businesses and all major geographies
  • Envista Business System (EBS) driving broad-based operational improvements
  • Spark clear aligners achieved positive operating margin in second half of 2025
  • Company-wide G&A expense reduced by 10% compared to 2024
  • 30% increase in customer training versus 2024

“With our disciplined focus on Growth, Operations, and People, Q4 2025 marked another quarter of continued progress for Envista. We delivered 10.8% core revenue growth and 22% adjusted EBITDA growth in Q425, and 6.5% core revenue growth and 26% EBITDA growth for the full-year 2025. In the process, we posted positive growth in all major businesses and geographies, made broad-based improvements in employee development and engagement, and returned $166 million to shareholders through share repurchases. Congratulations to our teams around the world for making all this progress possible.”

Envista CEO, on the earnings call

Forward Guidance & Outlook

For full year 2026, Envista guided core sales growth of 2% to 4%, adjusted EBITDA growth of 7% to 13%, adjusted diluted EPS of $1.35 to $1.45, and free cash conversion of approximately 100%. The company does not provide forward-looking estimates on a GAAP basis.

NVST YoY Financials

Q4 2025 vs Q4 2024 · SEC filings Q4 2024 Q4 2025
$0$300.0M$600.0M$652.9M$750.6MRevenue$373.3M$410.6MGross Profit$46.1M$73.3MOperating Income$1.2M$32.9MNet Income
$0$300.0M$600.0MRevenueGross ProfitOperating IncomeNet Income

NVST Revenue by Segment

Specialty Products & Technologies$475.9M+15.8%
Equipment & Consumables$274.7M+13.5%

Figures from SEC filings and company reports. Not investment advice.